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Complex patients present with numerous risk factors
and disease states. Clinical uses of biomarkers include
diagnosis (establishing or excluding the cause of undif-
ferentiated symptoms, understanding specific pathogenic
mechanisms, or identifying concomitant conditions),
risk stratification (assessing future risk of adverse out-
comes or monitoring risk of adverse events), screening,
and guiding therapy. Plasma natriuretic peptide are
released from the heart in response to volume overload,
as well as serving as markers of elevated filling pres-
sures, a finding that in many cases would otherwise only
be detectable with invasive testing. Therefore, the use of
natriuretic peptides is an important adjunct to echocar-
d i o g r a p h yi nm a n yc i r c u m s tances. Just as BNP levels
can be considered the arbitrator of CHF, cardiac tropo-
nins (TnI/TnT) are decisive for myocardial necrosis.
The introduction of novel assays with even higher clini-
cal sensitivity, detecting troponin levels at nanogram
quantities, suggest even earlier diagnosis of acute myo-
cardial infarction and identification of patients at sub-
stantial risk post-infarction. NGAL is one of the earliest
and most robustly induced genes and proteins in the
kidney after ischemic or nephrotoxic injury. Elevations
are detectable within hours of acute kidney injury (AKI);
whereas corresponding creatinine elevations lag 1 to 3
days behind.
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